Poster Presentations Session III
Poster Presentations Session III Tuesday, May 22, 2018
POSTERS SET-UP: 8:15 AM - 8:30 AM
POSTERS DISPLAY HOURS: 8:30 AM - 2:00 PM
POSTER AUTHOR DISCUSSION: 1:00 PM - 2:00 PM
POSTERS DISMANTLE: 2:00 PM


Poster display locations are shown below the poster codes
HEALTH CARE USE & POLICY STUDIES - Consumer Role in Health Care
PHP1
A1
WITHDRAWN

PHP2
A2
ANTECEDENTS OF PATIENT PARTICIPATION IN PRESCRIPTION MEDICATION DECISION
Ju I1, Park T2
1Saint Louis University, St Louis, MO, USA, 2St Louis College of Pharmacy, St Louis, MO, USA

PHP3
A3
PERCEIVED VALUE OF HEALTH INSURANCE AND ENROLLMENT DECISION AMONG LOW-INCOME POPULATION
Han J1, Ko D2
1Fairleigh Dickinson University, Florham Park, NJ, USA, 2Hankuk University of Foreign Studies, Seoul, Korea, Republic of (South)

PHP4
A4
AN EMPIRICAL EVALUATION OF PHARMACY “GAG” RULES IN THE US
Ballreich J1, Yehia F2
1Johns Hopkins Bloomberg School of Public Health, Department of Health Policy and Management, Baltimore, MD, USA, 2Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA

PHP5
A5
EMERGING PRIVATES: IDENTIFYING THE MAJOR MARKETS FOR PRIVATE HEALTHCARE EXPENDITURE
Macaulay R, Campbell J, Wang GD
PAREXEL International, London, UK

PHP6
A6
PATIENT ENGAGEMENT AS A PREDICTOR FOR HEALTH OUTCOMES AND COSTS IN MULTIPLE CHRONIC CONDITIONS
Ngorsuraches S, Da Rosa P, Ge X, Djira G, Michael S, Wey H
South Dakota State University, Brookings, SD, USA

PHP7
A7
WHAT DO WE MEAN BY PATIENT ENGAGEMENT? A QUALITATIVE CONTENT ANALYSIS OF CURRENT DEFINITIONS
Harrington RL1, Hanna ML2, Wheeler R3, Camp R4, Scott A5, Nguyen F6, Oehrlein EM2, Perfetto EM2, Patient Centered Special Interest Group LG7
1University of Illinois at Chicago, Chicago, IL, USA, 2University of Maryland School of Pharmacy, Baltimore, MD, USA, 3Leber's Hereditary Optic Neuropathy Society (LHON Society), Winchester, IL, UK, 4EUPATI Spain and EURORDIS, Barcelona, IL, Spain, 5KMK Consulting, Inc, Morristown, NJ, USA, 6Bayer Pharmaceuticals, Whippany, IL, USA, 7ISPOR, Lawrenceville, NJ, USA

HEALTH CARE USE & POLICY STUDIES - Disease Management
PHP8
WITHDRAWN

PHP9
A8
WITHDRAWN

PHP10
A9
COMBATTING RISING OBESITY IN AMCP DOSSIERS? THE NEW AMCP DOSSIER FORMAT – VERSION 4.0
Macaulay R, Mcnaughton E, Santi I, Samuels ER
PAREXEL International, London, UK

PHP11
A10
THE IMPACT OF ONLINE PATIENT COMMUNITIES ON PATIENT OUTCOMES: A SYSTEMATIC REVIEW
Bartolome L1, Choi M2, Yuan J3
1Thomas Jefferson University, Philadelphia, PA, USA, 2University of Maryland School of Pharmacy, Baltimore, MD, USA, 3Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

HEALTH CARE USE & POLICY STUDIES - Drug/Device/Diagnostic Use & Policy
PHP12
A11
IS THE ORPHAN DRUG ACT BEING USED AS A LOOPHOLE TO EXTEND PERIODS OF DRUG EXCLUSIVITY?
Padula WV1, Parasrampuria S1, Socal M1, Anderson G2
1Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA, 2Johns Hopkins University, Baltimore, MD, USA

PHP13
A12
RESULTS REPORTING IN CLINICALTRIALS.GOV AND PEER-REVIEWED PUBLICATIONS FOR TRIALS WITH THE SAME SPONSOR, DRUG AND CONDITION
Rajakannan T, Fain KM, Williams RJ, Zarin DA
National Institutes of Health, Bethesda, MD, USA

PHP14
A13
PRESCRIPTION DRUGS PRICES AND SOURCE OF PAYMENTS IN THE US FROM 1997 TO 2015
Tang W, Malone DC
University of Arizona, Tucson, AZ, USA

PHP15
A14
THE RELATIONSHIP BETWEEN MEDICAL INSURANCE COVERAGE AND MEDICATION PAYMENTS IN THE US FROM 1997 TO 2015
Tang W1, Malone DC2
1China Pharmaceutical University, Nanjing, China, 2University of Arizona, Tucson, AZ, USA

PHP16
A15
ASSESSING READINESS OF US COMMUNITY RHEUMATOLOGISTS FOR IMPLEMENTATION OF MEDICARE ACCESS AND CHIP REAUTHORIZATION ACT (MACRA), MERIT-BASED INCENTIVE PAYMENT SYSTEM (MIPS) AND ALTERNATIVE PAYMENT MODELS (APMS)
Radtchenko J1, Nabhan C2, Smith Y2, Feinberg B2
1Cardinal Health, Dublin, OH, USA, 2Cardinal Health Specialty Solutions, Dublin, OH, USA

PHP17
A16
EXAMINING THE TARGET POPULATION OF ORPHAN DRUGS: ARE DRUGS EXCEEDING THE INTENDED PURPOSES OF THE ORPHAN DRUG ACT?
Socal MP1, Patel P2, Parasrampuria S1, Padula WV1, Anderson G2
1Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA, 2Johns Hopkins University, Baltimore, MD, USA

PHP18
A17
WITHDRAWN

PHP19
A18
MANAGEMENT OF BIOSIMILARS: KEY CONSIDERATIONS FOR PHARMACISTS IN PATIENT CARE
Mohite N, Nayak R
St. John's University, Queens, NY, USA

PHP20
A19
INSURANCE MARKETPLACE ENROLLMENT AND IN-PERSON ASSISTANCE UNDER THE AFFORDABLE CARE ACT
Han J1, Ko D2
1Fairleigh Dickinson University, Florham Park, NJ, USA, 2Hankuk University of Foreign Studies, Seoul, Korea, Republic of (South)

PHP21
A20
WITHDRAWN

PHP22
A21
TOWARDS IRP COMMON GROUND: TO WHAT EXTENT ARE EUROPEAN COUNTRIES ALIGNED IN HOW THEY USE INTERNATIONAL REFERENCE PRICING?
Lockwood C1, Rodrigues T2, Genane C3, Su W4, Ando G2
1IHS Markit, Fremont, CA, USA, 2IHS Markit, London, UK, 3IHS Markit, Paris, France, 4IHS Markit, Washington, DC, USA

PHP23
A22
BIOSIMILAR MARKET ACCESS – COMPARING THE US AND EUROPEAN MARKETS
Macaulay R1, Hugon M2
1PAREXEL International, London, UK, 2PAREXEL, London, UK

PHP24
A23
ICER REPORTS – 4 YEARS OF COST/QALY DRUG EVALUATIONS IN THE USA… WHAT DOES THE FUTURE HOLD?
Macaulay R, Majeed B, Mcnaughton E, Anastasaki E
PAREXEL International, London, UK

PHP25
A24
PHARMACEUTICAL EXPENDITURES, OUT OF POCKET COSTS, AND IMPACT OF PROVIDER FACTORS: INTERSECTION OF HEALTH ECONOMICS AND THE MARKETING MIX
Mantravadi S
, -, FL, USA

PHP26
A25
HEALTH INSURANCE COST RELATED TO THE ADDITIONAL TREATMENT AND COMPLICATIONS OF PATIENTS INVOLVED INTO CLINICAL TRIALS
Boncz I1, Répássy B1, Csákvári T2, Kovács G3, Endrei D1
1University of Pécs, Pécs, Hungary, 2University of Pécs, Zalaegerszeg, Hungary, 3Széchenyi István University, Győr, Hungary

PHP27
A26
UPDATED NEW DRUGS APPROVAL TIMING IN ITALY (2015-2017)
Lidonnici D1, Lanati EP1, Niedecker S2, Isernia M1
1MA Provider Srl, Milano, Italy, 2MAProvider Sagl, Lugano, Switzerland

PHP28
A27
NEW DRUGS APPROVAL IN ITALY: UPDATED ANALYSIS OF THE APPLIED NEGOTIATION CONDITIONS 2015-2017
Lidonnici D1, Lanati EP1, Niedecker S2, Isernia M1
1MA Provider Srl, Milano, Italy, 2MAProvider Sagl, Lugano, Switzerland

PHP29
A28
THE ELEPHANT(S) IN THE ROOM – AGGRANDIZEMENT OF STA GUIDANCE WORKLOAD FOR NICE
Macaulay R, Edmonson-Jones M, Sutcliffe D, Wang GD
PAREXEL International, London, UK

PHP30
A29
THE IMPACT OF LEGISLATIVE CHANGES AND REGULATORY GUIDANCE ON PROACTIVE DISSEMINATION OF HEALTHCARE ECONOMIC INFORMATION: PAYERS’ EXPERIENCES PRE AND POST PRODUCT APPROVAL
Begovic E1, Duhig A1, Jackson J1, Kaufman S1, Hughes J1, Sarnes M1, Saha S2
1Xcenda, LLC, Palm Harbor, FL, USA, 2Academy of Managed Care Pharmacy, Alexandria, VA, USA

PHP31
A30
STATE OF THE ART AND FUTURE PERSPECTIVES OF ADVANCED THERAPY MEDICINAL PRODUCTS IN ITALY AND IN THE INTERNATIONAL ARENA
Lidonnici D1, Ronco V1, Niedecker S2, D'Ausilio A1, Lanati EP1
1MA Provider Srl, Milano, Italy, 2MAProvider Sagl, Lugano, Switzerland

PHP32
A31
IMPACT OF 2017 POLICY CHANGES ON CHINA'S PHARMACEUTICAL MARKET
Chen XH1, Ribeiro A2
1Lifescience Dynamics, London, UK, 2Lifescience Dynamics, Boston, MA, USA

PHP33
A32
PHYSICIANS’ PERCEIVED AWARENESS OF PATIENTS’ MEDICATIONS: A CROSS-SECTIONAL SURVEY
Cheng N, Hohmann N, Hastings TJ, Li C, Qian J, Chou C, Hansen RA
Auburn University Harrison School of Pharmacy, Auburn, AL, USA

PHP34
A33
BIOSIMILARS: BARRIERS AND OPPORTUNITIES TO MARKET ACCESS IN THE UNITED STATES
Chopra I, Arkells N, Chopra AS
Manticore Consulting Group, Scottsdale, AZ, USA

PHP35
A34
POLICIES AND PROCESSES APPLICABLE TO DRUGS FOR VERY RARE DISEASES IN AUSTRALIA, CANADA, ENGLAND, FRANCE AND GERMANY
Moorhouse JA, Ellis H, Horscroft JA, Chapman A, Akehurst R
BresMed Health Solutions, Sheffield, UK

PHP36
A35
US PAYER PERSPECTIVES ON VALUE AND COMPARISONS OUTSIDE THE US: AN INTERVIEW STUDY
Brogan AP, Mauskopf J
RTI Health Solutions, Durham, NC, USA

PHP37
A36
PAYER PERSPECTIVES ON GENE THERAPY REIMBURSEMENT IN THE UNITED STATES
Yang M, Young D, Teagarden JR, Barlow JF
Massachusetts Institute of Technology, Cambridge, MA, USA

PHP38
A37
BIOSIMILAR REGULATORY POLICIES ISSUES AND IMPLICATIONS: WHERE ARE WE HEADED?
Arkells N, Chopra AS, Chopra I
Manticore Consulting Group, Scottsdale, AZ, USA

PHP39
A38
ARE FDA ACCELERATED APPROVALS UNCONDITIONAL APPROVALS?
Macaulay R, Tsang R
PAREXEL International, London, UK

PHP40
A39
TRENDS IN APPROVAL OF THERAPEUTIC BIOLOGIC APPROVED BY THE US FOOD AND DRUG ADMINISTRATION (1986–2017)
Kim J1, Min E1, Nishikawa K1, Patel P1, Rouzitalab L1, Tomaszewski DM2, Seoane-Vazquez E1
1Chapman University, Irvine, CA, USA, 2Chapman University, School of Pharmacy, Irvine, CA, USA

PHP41
A40
BARRIERS IMPEDING THE AVAILABILITY AND UPTAKE OF BIOSIMILARS IN THE US
Phelps G1, Wang J2, Schwab CA1, Li MS1
1University of Tennessee Health Science Center, Memphis, TN, USA, 2The University of Tennessee Health Science Center College of Pharmacy, Memphis, TN, USA

PHP42
A41
CONSISTENCY OF DRUG LABELS FOR THERAPEUTICALLY EQUIVALENT MEDICATIONS
Kiptanui Z1, Dowell P1, Ogbenna B1, Desai K1, Zenilman D1, Harris I1, Qian J2, Hansen RA2
1IMPAQ International, Columbia, MD, USA, 2Auburn University Harrison School of Pharmacy, Auburn, AL, USA

PHP43
A42
IMPLICATIONS OF BREXIT ON EUROPEAN PHARMACEUTICAL MARKET ACCESS
Wang GD, Macaulay R
PAREXEL International, London, UK

PHP44
A43
WITHDRAWN

PHP45
A44
WITHDRAWN

PHP46
A45
CHARACTERIZATION OF DRUG UTILIZATION STUDIES (DUS) SUBMITTED TO THE EUROPEAN UNION (EU) ELECTRONIC REGISTER OF POST-AUTHORISATION STUDIES (PAS)
Palacios L1, De Cock E2
1Syneos Health, Madrid, Spain, 2Syneos Health, Barcelona, Spain

PHP47
A46
WITHDRAWN

PHP48
A47
ATTITUDE OF HEALTHCARE PROFESSIONALS TOWARDS UNDERSTANDING THE ISSUE OF ANTIMICROBIAL RESISTANCE
Zubair M1, Hussain T2
1Peshawar Medical and Dental College, Peshawar, Pakistan, 2Abdul Wali Khan University Mardan, Mardan, Pakistan

PHP49
A48
A RETROSPECTIVE DATABASE ANALYSIS OF USAGE OF CHINESE PATENT MEDICINE IN CHINA IN THE YEARS 2015 & 2016
Ma Y1, Gao S2, Feng X3, Yang L3, Yu N3
1China Health Insurance Research Association, Beijing, China, 2Beijing North Medical & Health Economic Research Center, Beijing, China, Beijing, China, 3Beijing Brainpower Pharma Consulting Co. Ltd, Beijing, China

PHP50
A49
FACTORS PREDICTING RESTRICTIONS ON US COMMERCIAL PAYER COVERAGE OF SPECIALTY DRUGS
Kim DD1, Pope E1, Wilkinson CL2, Graff JS3, Neumann PJ1, Chambers JD1
1Tufts Medical Center, Boston, MA, USA, 2Center for the Evaluation of Value and Risk in Health, Institute for Clinical Research and Health Policy Studies,Tufts Medical Center, Boston, MA, USA, 3National Pharmaceutical Council, Washington, DC, USA

PHP51
A50
THE PROFESSIONALS’ PERSPECTIVE OF PATIENT INVOLVEMENT IN MARKET ACCESS: A DESCRIPTIVE ANALYSIS
Fatoye C1, Betts A2, Odeyemi A3, Fatoye F2, Odeyemi I2
1HEMAC, MANCHESTER, UK, 2Manchester Metropolitan University, Manchester, UK, 3Cureativ-Ceutical Limited, London, UK

PHP52
B1
BIOSIMILAR INFLIXIMAB UTILIZATION AFTER PATENT EXPIRY: THE CASE OF COLITIS ULCEROSA AND RHEUMATOID ARTHRITIS IN HUNGARY
Harsányi A1, Csanádi M2, Márky K3, Németh B4, Vincziczki ÁZ3, Kaló Z5, Inotai A1
1Eötvös Loránd University (ELTE), Budapest, Hungary, 2University of Pécs, Pécs, Hungary, 3National Institute of Health Insurance Fund Management, Budapest, Hungary, 4Syreon Research Institute, Budapest, Hungary, 51. Eötvös Loránd University (ELTE), 2. Syreon Research Institute, Budapest, Hungary

PHP53
B2
ACCEPTING BIOSIMILARS - WHAT ARE THE DOCTORS LOOKING FOR? - A SYSTEMATIC REVIEW.
Sawant RV, Sansgiry SS
College of Pharmacy, University of Houston, Houston, TX, USA

PHP54
B3
DEFINING POLYPHARMACY AS A COUNT OF MEDICATIONS: WHAT IS THE OPTIMAL CUT-POINT?
Schiltz NK, Olaisen RH
Case Western Reserve University, Cleveland, OH, USA

PHP55
B4
IDENTIFICATION OF POTENTIALLY INAPPROPRIATE CARDIOVASCULAR PRESCRIPTIONS IN THE ELDERLY USING BEERS CRITERIA IN COLOMBIA.
Machado-Duque M1, Castro-Rodriguez A2, Medina-Morales D3, Machado-Alba J4
1Universidad Tecnológica de Pereira - Fundación Universitaria Autónoma de las Américas - Audifarma S.A, Pereira, Colombia, 2Universidad Tecnológica de Pereira, Pereira, Colombia, 3Audifarma S.A, Pereira, Colombia, 4Universidad Tecnológica de Pereira-Audifarma S.A., Pereira, Colombia

PHP56
B5
FACTORS RELATED TO NON-INTEGRATED OR FRAGMENTATION POLYPHARMACY IN A COLOMBIAN POPULATION
Castro-Rodriguez A1, Machado-Duque M2, Gaviria-Mendoza A3, Medina-Morales D4, Álvarez-Vera T1, Machado-Alba J5
1Universidad Tecnológica de Pereira, Pereira, Colombia, 2Universidad Tecnológica de Pereira - Fundación Universitaria Autónoma de las Américas - Audifarma S.A, Pereira, Colombia, 3Audifarma S.A., Pereira, Colombia, 4Audifarma S.A, Pereira, Colombia, 5Universidad Tecnológica de Pereira-Audifarma S.A., Pereira, Colombia

PHP57
B6
LONG-TERM USERS OF BENZODIAZEPINES IN COLOMBIA: PATTERNS OF USE AND CESSATION OF TREATMENT
Moreno-Gutierrez PA1, Gaviria-Mendoza A2, Ochoa-Orozco SA3, Yepes-Echeverri MC3, Machado-Alba J3
1Audifarma S.A, Pereira, Colombia, 2Audifarma S.A., Pereira, Colombia, 3Universidad Tecnológica de Pereira-Audifarma S.A., Pereira, Colombia

PHP58
B7
TRENDS OF ANTIBIOTIC CONSUMPTION IN INTENSIVE CARE UNITS OF COLOMBIA, 2010-2016
Machado-Alba J1, Sanchez-Duque J1, Gómez-González JF2, Moreno-Gutierrez PA3, Pantoja-Meneses SA1, Thahir-Silva S1, Gaviria-Mendoza A4
1Universidad Tecnológica de Pereira-Audifarma S.A., Pereira, Colombia, 2Universidad Tecnológica de Pereira, Pereira, Colombia, 3Audifarma S.A, Pereira, Colombia, 4Audifarma S.A., Pereira, Colombia

PHP59
B8
WITHDRAWN

PHP60
B9
WITHDRAWN

PHP61
B10
WITHDRAWN

HEALTH CARE USE & POLICY STUDIES - Equity and Access
PHP62
B11
ANALYSIS OF HEALTH INSURANCE COVERAGE BY CITIZENSHIP STATUS IN THE UNITED STATES
Lal TS1, Chung TH2, Nguyen LK3, Lal L3
1University of Houston, Houston, TX, USA, 2UT Health, Houston, TX, USA, 3University of Texas School of Public Health, Houston, TX, USA

PHP63
B12
AVAILABILITY OF PHARMACIES PARTICIPATING IN THE 340B DRUG PRICING PROGRAM, 2016
Guadamuz J1, Qato D2
1Department of Pharmacy Systems, Outcomes and Policy, University of Illinois at Chicago, Chicago, IL, USA, 2University of Illinois at Chicago, Chicago, IL, USA

PHP64
B13
IMPLEMENTATION OF THE SOUTH AFRICAN TRIAGING SCALE (SATS) SYSTEM IN EASTERN GHANA: ASSESSMENT OF DEPLOYMENT AT THE EMERGENCY DEPARTMENT OF A REGIONAL HOSPITAL, 2015
Addai L1, Davies-Teye B2, Anim-Boamah K3, Sarpong C3, Antwi-Agyei K4
1Eastern Regional Hospital, Ghana Health Service, Koforidua, Ghana, 2Ghana Health Service and Drifney Consult Ltd, Accra, Ghana, 3Ghana Health Service, Koforidua, Ghana, 4Ghana College of Physicians and Surgeons, Accra, Ghana

PHP65
B14
EXAMINING COSTS, UTILIZATION, AND DRIVING FACTORS OF COMPLEMENTARY AND ALTERNATIVE MEDICINE (CAM) SERVICES
Lewing B, Sansgiry SS
College of Pharmacy, University of Houston, Houston, TX, USA

PHP66
B15
PREVALENCE AND CORRELATES OF PHARMACY CLOSURE IN THE UNITED STATES, 2009-2015
Guadamuz J1, Alexander GC2, Zenk S3, Qato D3
1Department of Pharmacy Systems, Outcomes and Policy, University of Illinois at Chicago, Chicago, IL, USA, 2Johns Hopkins University, Baltimore, MD, USA, 3University of Illinois at Chicago, Chicago, IL, USA

PHP67
B16
EXAMINING THE IMPACT OF ARKANSAS MEDICAID EXPANSION THROUGH PREMIUM PURCHASE ON UTILIZATION OF PREVENTATIVE SCREENING SERVICES
Kathe N1, Chopra DA1, Bhandari NR1, Moore G1, Lewis K2, Li C1, Goudie A3, Martin BC1
1University of Arkansas for Medical Sciences, Little Rock, AR, USA, 2Arkansas Center for Health Improvement, Little Rock, AR, USA, 3Arkansas Children's Hospital, Little Rock, AR, USA

PHP68
B17
ACCESSING MEDICATIONS IN THE UNITED STATES: A SYSTEMIC REVIEW OF THE CHALLENGES AND BARRIERS
Holland L1, Mehas N2, Pickering M2, Westrich KD3
1East Tennessee State University, Johnson City, TN, USA, 2Pharmacy Quality Alliance, Alexandria, VA, USA, 3National Pharmaceutical Council, Washington, DC, USA

PHP69
B18
CHALLENGES TO REDUCING LOW-VALUE CARE: LESSONS LEARNED AND FUTURE DIRECTIONS
Sorenson C, Schauer L, McClellan M
Duke University, Durham, NC, USA

PHP70
B19
THE ROLE OF GENERAL PRACTITIONERS DURING ECONOMIC CRISES
Shrestha D
Hankuk University of Foreign Studies, Seoul, Korea, Republic of (South)

PHP71
B20
SCREENING FOR AND ADDRESSING SOCIAL DETERMINANTS OF HEALTH IN MANAGED CARE
McInerney M, Blank S, Connaughton J, Keleti D, Michael KE, Gelzer AD
AmeriHealth Caritas, Philadelphia, PA, USA

PHP72
B21
A TALE OF TWO DTM PROGRAMS: DRUG THERAPY MANAGEMENT REDUCES ACUTE HOSPITALIZATION AND EXPENDITURES IN MEDICAID BENEFICIARIES IN MICHIGAN AND WASHINGTON DC
Cherian S1, Shull SM1, Maiorini A1, Gao W2, Pradhan S2, Keleti D2, Jones J2, Michael KE2, Dale KM3, Chan H4, Gelzer AD2
1PerformRx, Philadelphia, PA, USA, 2AmeriHealth Caritas, Philadelphia, PA, USA, 3AmeriHealth Caritas District of Columbia, Washington, DC, DC, USA, 4Blue Cross Complete of Michigan, Southfield, MI, USA

PHP73
B22
ACCESS TO HEALTH INSURANCE AMONG NONELDERLY ADULTS WITH COMPLEX MULTIMORBIDITY AFTER PASSAGE OF THE AFFORDABLE CARE ACT
McRae JM, Olopoenia A, Qato DM, Camelo Castillo W
University of Maryland School of Pharmacy, Baltimore, MD, USA

PHP74
B23
IMPROVING THE QUALITY AND EFFICIENCY OF CARE DELIVERY THROUGH IN-DEPTH UNDERSTANDING OF THE CHINA HEALTHCARE DIGITAL LANDSCAPE
Han Y1, Li A2
1WPP Health and Wellness/WG Consulting, New York, NY, USA, 2Kantar Health, Shanghai, China

PHP75
B24
MULTI-LEVEL PREDICTORS OF DISCHARGES AGAINST MEDICAL ADVICE: DECOMPOSING VARIATION USING AN ALL-PAYER DATABASE.
Nagarajan M1, Onukwugha E1, Offurum AI2, Gulati M2, Alfandre D3
1University of Maryland School of Pharmacy, Baltimore, MD, USA, 2University of Maryland Medical School of Medicine, Baltimore, MD, USA, 3New York University School of Medicine, New York, NY, USA

PHP76
B25
HOW ARE WE MEASURING ACCESS TO HEALTHCARE IN THE US? — AN ENVIRONMENTAL SCAN OF QUALITY MEASURES
Mehas N1, Nelson M1, Pickering M1, Ashemore A2, Westrich KD3
1Pharmacy Quality Alliance, Alexandria, VA, USA, 2Presbyterian College School of Pharmacy, Clinton, SC, USA, 3National Pharmaceutical Council, Washington, DC, USA

HEALTH CARE USE & POLICY STUDIES - Formulary Development
PHP77
B26
WITHDRAWN

PHP78
B27
ROLE OF PATIENT ASSISTANCE PROGRAM (PAP) IN MARKET ACCESS AND OUTCOMES: INSIGHTS FROM SYSTEMATIC LITERATURE REVIEW (2013-2017)
Aggarwal S1, Topaloglu O1, Kumar S2
1NOVEL Health Strategies, Chevy Chase, MD, USA, 2Institute for Global Policy, Washington, DC, USA

PHP79
B28
THE 2018 US PAYOR LANDSCAPE: TRENDS AND RESULTS FROM FORMULARY MANAGEMENT SURVEYS
Brook RA1, Carlisle JA2, Smeeding JE3
1The JeSTARx Group & TPG-NPRT, Newfoundland, NJ, USA, 2The TPG-NPRT, Glastonbury, CT, USA, 3The TPG-NPRT & JeSTARx, Glastonbury, CT, USA

PHP80
B29
INCLUSION OF DRUGS IN A FORMULARY: A CASE STUDY
Jaraki J1, Levy X1, Palacios E2, Zapata L2, Aguilar JL3, Marquez M3
1Florida Atlantic University, Boca Raton, FL, USA, 2Guia Mark, Mexico - D.F, Mexico, 3Vitamédica S.A. de C.V., Ciudad de México, Mexico

PHP81
B30
ESTIMATION OF SUPPLY SIDE COST EFFECTIVENESS THRESHOLD IN UKRAINE: PERSPECTIVE USE IN HEALTH CARE DECISION-MAKING
Topachevskyi O1, Piniazhko O1, Lebega O2, Oleshchuk O1
1National EML Committee, Kiev, Ukraine, 2Technical SAFEMED Advisor, Kiev, Ukraine

HEALTH CARE USE & POLICY STUDIES - Health Care Costs & Management
PHP82
B31
UTILIZATION EVALUATION OF ANTIBIOTICS AT CRITICAL CARE SETTING OF A TERTIARY CARE HOSPITAL
Patel DS, Awhamefule UI, Joy JE, Pakalapati N, Madhan R
Jagadguru Sri Shivarathreeswara University, Mysuru, India

PHP83
B32
ARE WHOLE EXOME AND WHOLE GENOME SEQUENCING APPROACHES COST-EFFECTIVE? A SYSTEMATIC REVIEW OF THE LITERATURE
Schwarze K, Buchanan J, Taylor JC, Wordsworth S
University of Oxford, Oxford, UK

PHP84
B33
ASSESSING THE BURDEN OF DISEASE-ASSOCIATED MALNUTRITION AMONG HOSPITALIZED MALNOURISHED COLOMBIAN PATIENTS WITH HEART AND LUNG DISEASE
Ruiz A1, Misas JD2, Gomez G2, Sulo S3, Dennis RJ4, Buitrago G1, Rodriguez N1, Gomez C5, Alba M6, Chaves W7, Araque C8
1Pontificia Universidad Javeriana Medical School, Bogota, Colombia, 2Abbott, Bogota, Colombia, 3Abbott Nutrition, Abbott Park, IL, USA, 4Fundación Cardioinfantil, Bogotá, Colombia, 5Pontificia Universidad Javeriana, Bogota, Colombia, 6Fundación Universitaria de Ciencias de la Salud., bogota, Colombia, 7Hospital Universitario de San José., Bogota, Colombia, 8Hospital Universitario Infantil de San José., Bogota, Colombia

PHP85
B34
SHIFT IN THE STATUS QUO: HOW BIOSIMILAR INTERCHANGEABILITY CAN LEAD TO SIGNIFICANT COST SAVINGS
Chopra AS1, Chopra I1, Giardina C2, Arkells N1
1Manticore Consulting Group, Scottsdale, AZ, USA, 2University of Connecticut, Storrs, CT, USA

PHP86
B35
CORRELATES OF ONCOLOGY DRUG PRICES IN THE U.S.
Haong W, Shcherbakova N
Western New England University College of Pharmacy and Health Sciences, Springfield, MA, USA

PHP87
B36
COST-MINIMIZATION ANALYSIS OF DEXMEDETOMIDINE COMPARED TO PROPOFOL AND MIDAZOLAM FOR SHORT-TERM SEDATION IN THE UNITED STATES
Sanders KN1, Aggarwal J2, Lustrino JM2, Katkade V3, Stephens JM4
1Pfizer, Inc, New York, NY, USA, 2Pharmerit International, Newton, MA, USA, 3Pfizer, Inc., Collegeville, PA, USA, 4Pharmerit International, Bethesda, MD, USA

PHP88
B37
PREDICTORS OF ANNUAL SALARY FOR HEALTH ECONOMICS, OUTCOMES RESEARCH, AND MARKET ACCESS PROFESSIONALS
Ghosh S1, Rascati KL1, Shah A2, Peeples P2
1The University of Texas at Austin, Austin, TX, USA, 2HealthEconomics.Com, Ponte Vedra Beach, FL, USA

PHP89
B38
WITHDRAWN

PHP90
B39
COST DRIVERS IN PUBLIC DRUG PLANS IN CANADA, 2016/17
Lungu E1, Bosnic N2, Zhang Y2
1Patented Medicine Prices Review Board, Ottawa, ON, Canada, 2PMPRB, Ottawa, ON, Canada

PHP91
B40
ECONOMIC IMPACT OF CALCIUM FREE BALANCED SOLUTION VERSUS 0.9% SALINE IN SIRS PATIENTS: A BRAZILIAN PUBLIC HOSPITAL PERSPECTIVE.
Menezes FG1, Otuyama LJ2, Tolentino RB2, Gresse Junior S1, Pinto VB2, Sforsin AC2, Ariza JG3
1Baxter Hospitalar, SÃO PAULO, Brazil, 2Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil, 3BAXTER, BOGOTA, Colombia

PHP92
B41
PREVALENCE AND FACTORS ASSOCIATED WITH HOSPITAL ADMISSION AMONG US ADULTS: NHANES 2005-2014
Park L1, Rodriguez de Bittner M2, Shaya FT2
1University of Maryland Baltimore, Baltimore, MD, USA, 2University of Maryland School of Pharmacy, Baltimore, MD, USA

PHP93
B42
WITHDRAWN

PHP94
B43
BUDGET IMPACT MODEL OF LOW CHLORIDE BALANCED INTRAVENOUS SOLUTIONS IN PATIENTS WITH SYSTEMIC INFLAMMATORY RESPONSE SYNDROME FROM A HOSPITAL PERSPECTIVE IN COLOMBIA
Hubert MM1, Tomaras D1, Vezina E1, Sabogal JE2, Ciro JD3, Ariza JG4, Sampalis J1
1JSS Medical Research, Montreal, QC, Canada, 2Nueva EPS, Cali, Colombia, 3Clinica de las Americas, Medellin, Colombia, 4BAXTER, BOGOTA, Colombia

PHP95
B44
WITHDRAWN

PHP96
B45
A RETROSPECTIVE OBSERVATIONAL STUDY ON CHARACTERISTICS AND MEDICAL RESOURCE UTILIZATION OF LONG-TERM HOSPITALIZATION PATIENTS IN CHINA
Zhang J1, Liu M2, Yang L2, Ma Y1, Yu N2
1China Health Insurance Research Association, Beijing, China, 2Beijing Brainpower Pharma Consulting Co. Ltd, Beijing, China

PHP97
B46
ECONOMIC IMPACT OF FRENCH PUBLIC REGULATIONS ON FERRIC CARBOXYMALTOSE IN 39 PARIS PUBLIC HOSPITALS OVER THE 2013-2016 PERIOD
Monirul S1, Bocquet F2, Degrassat-Théas A3, Poisson N4, Therasse C5, Parent de curzon O6, Paubel P7
1General Agency of Equipment and Health Products (AGEPS), University public Hospitals of Paris (AP-HP), Paris, France, 2General Agency of Equipment and Health Products (AGEPS), Assistance Publique-Hôpitaux de Paris (AP-HP) ; Faculty of Pharmacy, Paris Descartes University, Sorbonne Paris Cité, Paris, France, Paris, France, 3General Agency of Equipment and Health Products (AGEPS), Assistance Publique-Hôpitaux de Paris (AP-HP) ; Faculté of pharmacy, Paris Descartes University, Sorbonne Paris Cité, Paris, France; Law and Health Economics Department, Faculty of Pharmacy, Paris D, Paris, France, 4AP-HP, AGEPS, Paris, France, 5General Agency of Equipment and Health Products (AGEPS), Assistance Publique-Hôpitaux de Paris (AP-HP), Paris, France, 6General Agency of Equipment and Health Products (AGEPS), Assistance Publique-Hôpitaux de Paris (AP-HP) ; Faculté of pharmacy, Paris Descartes University, Sorbonne Paris Cité, Paris, France, Paris, France, 7General Agency of Equipment and Health Products (AGEPS), Assistance Publique-Hôpitaux de Paris (AP-HP); Health Law Institute, INSERM UMR S 1145, Paris Descartes ; Faculté of pharmacy, Paris Descartes University, Sorbonne Paris Cité, Paris, France

PHP98
C1
WITHDRAWN

PHP99
C2
AN INTERNATIONAL COMPARISON OF ANTINEOPLASTIC AND IMUNOMODULATING AGENT PRICE IN THIRTEEN COUNTRIES : PATENTED MEDICINES, CHEMICAL ENTITIES, AND BIOLOGICS
Cho H, Son K, Bae S
Ewha Womans University, Seoul, Korea, Republic of (South)

PHP100
C3
THE INFLUENCING OF HOSPITALIZATION COSTS THROUGH LENGTH OF STAY AMONG INPATIENTS WITH POSITIVE ANTIMICROBIAL SUSCEPTIBILITY BASED ON THE METHOD OF STRUCTURAL EQUATION MODEL
Zhen X1, Sheng YY2, Dong H1
1Zhejiang Unviersity, Hangzhou, China, 2Princeton Unversity, Princeton, NJ, USA

PHP101
C4
WITHDRAWN

PHP102
C5
SYSTEMATIC REVIEW OF THE ECONOMIC BURDEN OF ANTIBIOTIC RESISTANCE
Zhen X, Hu X, Dong H
Zhejiang Unviersity, Hangzhou, China

PHP103
C6
ANALYSIS OF MINIMIZATION OF COSTS OF EQUIVALENT THERAPEUTIC ALTERNATIVES (ATE) IN A GENERAL HOSPITAL OF BELO HORIZONTE / MG, BRAZIL.
Silva WC1, Sebastiao E2, Dias EP3, Domingues S1, Cherchiglia ML4, Acurcio FA5, Andrade EI1, Leite R2
1Federal University of Minas Gerais, Belo Horizonte, Brazil, 2Federal University of Ouro Preto Minas Gerais, Ouro Preto - MG, Brazil, 3Hospital Felicio Rocho/Fundação Felice Rosso, Belo Horizonte, Brazil, 4Federal University of Minas Gerais, BELO HORIZONTE, Brazil, 5Universidade Federal de Minas Gerais, Belo Horizonte, Brazil

PHP104
C7
ECONOMIC VALUE TOOL EVALUATING TOTAL PROCEDURAL COSTS ASSOCIATED WITH THE CREATION OF COLORECTAL ANASTOMOSES
Ditto R1, Roy S2
1Ethicon Inc, Cincinnati, OH, USA, 2Ethicon Inc, Somerville, NJ, USA

PHP105
C8
CHANGES OF HEALTH INSURANCE SICK-PAY EXPENDITURES IN HUNGARY BETWEEN 2008-2016
Kovács G1, Endrei D2, Sebestyén A2, Csákvári T3, Molics B2, Boncz I2
1Széchenyi István University, Győr, Hungary, 2University of Pécs, Pécs, Hungary, 3University of Pécs, Zalaegerszeg, Hungary

PHP106
C9
DISCOUNTS OFFERED BY FIRST AND SUBSEQUENT BIOSIMILARS IN THE US, EU AND LATAM: IMPACT TRENDS OF ORIGINATOR STARTING PRICE, MARKET DYNAMICS AND REGULATIONS
Heredia E1, Ribeiro A2
1Lifescience Dynamics, London, UK, 2Lifescience Dynamics, Boston, MA, USA

PHP107
C10
DEFICIT OF THE HUNGARIAN HEALTH INSURANCE FUND BETWEEN 1994-2014
Endrei D1, Sebestyén A1, Ágoston I1, Csákvári T2, Kovács G3, Boncz I1
1University of Pécs, Pécs, Hungary, 2University of Pécs, Zalaegerszeg, Hungary, 3Széchenyi István University, Győr, Hungary

PHP108
C11
GLOBAL GROWTH IN PUBLIC HEALTHCARE: EMERGING MARKETS TAKE THE WHEEL
Macaulay R, Campbell J, Wang GD
PAREXEL International, London, UK

PHP109
C12
PRODUCTIVITY GROWTH OF SKILLED NURSING FACILITIES IN TREATING POST-ACUTE-CARE-INTENSIVE CONDITIONS
Gu J, Romley JA, Sood N
University of Southern California, Los Angeles, CA, USA

PHP110
C13
REVIEW OF OPERATIVE OUTCOMES OF ROBOTIC SURGICAL PROCEDURES PERFORMED WITH ROBOTIC VS. ENDOSCOPIC LINEAR STAPLERS
Gutierrez M1, Ditto R1, Roy S2
1Ethicon Inc, Cincinnati, OH, USA, 2Ethicon Inc, Somerville, NJ, USA

PHP111
C14
ANALYSIS OF SOCIODEMOGRAPHIC DETERMINANTS OF ADVERSE DRUG EVENTS: USING THE NATIONAL INPATIENT SAMPLE DATABASE
Sherbeny F1, Lamoureux J2, Lai L3, Bleidt BA3
1Nova Southeastern University, Davie, FL, USA, 2Dimensional Insight, Burlington, MA, USA, 3Nova Southeastern University, Fort Lauderdale, FL, USA

PHP112
C15
TESTOSTERONE REPLACEMENT THERAPY REDUCES CARDIOVASCULAR EVENTS IN MEN WITH CHRONIC KIDNEY DISEASE
Chen J1, Adjei Boakye E1, McKee AM2, Dhindsa SS2
1Saint Louis University Center for Outcomes Research, Saint Louis, MO, USA, 2Saint Louis University School of Medicine, Saint Louis, MO, USA

PHP113
C16
LOW BIRTH WEIGHT IN NEWBORNS AND ASSOCIATED MATERNAL AND NEONATAL FACTORS IN A COLOMBIAN GINECO-OBSTETRICAL HOSPITAL
Alvis Zakzuk J1, Zakzuk Sierra J2, Alvis Zakzuk NR1, herrera Rodriguez MA1, Edna Estrada F3, Linero Bolaño MI3, Alvis Guzman N4
1ALZAK Foundation, Centro de investigación Seguridad Materna - Grupo de investigacion para la salud materna, perinatal y de la mujer - Clínica Maternidad Rafael Calvo, CARTAGENA, Colombia, 2Alzak Foundation. Universidad de Cartagena., Cartagena de Indias, Colombia, 3Centro de Investigación para la Salud Materna Perinatal y de la Mujer. Clinica Maternidad Rafael Calvo C., Cartagena de Indias, Colombia, 4Universidad de Cartagena - ALZAK Foundation, Cartagena, Colombia

PHP114
C17
EVALUATION OF POTENTIALLY INAPPROPRIATE MEDICATIONS AND CLINICAL OUTCOMES IN OLDER ADULTS ADMITTED TO THE MEDICAL INTENSIVE CARE UNIT
Rahman M, Keeton AN, Conner AC, Qian J, Bulloch MN
Auburn University Harrison School of Pharmacy, Auburn, AL, USA

PHP115
C18
VENO-OCCLUSIVE DISEASE (VOD) ASSOCIATED WITH GEMTUZUMAB OZOGAMICIN (GO) AND INOTUZUMAB OZOGAMICIN: ANALYSIS OF THE FDA ADVERSE EVENT REPORTING SYSTEM
Alsultan M1, Guo JJ2, Schwartz R2
1University of Cincinnati, cincinnati, OH, USA, 2University of Cincinnati, Cincinnati, OH, USA

PHP116
C19
INCIDENCE OF SUBSEQUENT LUMBAR SURGERY FOLLOWING POSTERIOR LUMBAR FUSION
Corso KA1, Etter K2, Menzie AM3, Bhattacharyya S3, Pracyk JB4
1Johnson & Johnson, New Brunswick, NJ, USA, 2Johnson & Johnson Medical Devices, Raynham, MA, USA, 3DePuy Synthes, Inc., Raynham, MA, USA, 4Johnson & Johnson, Raynham, MA, USA

PHP117
C20
WITHDRAWN

PHP118
C21
INCIDENCE OF MALIGNANT NEOPLASM FOR PATIENTS USING BIOLOGIC DRUGS: A NESTED CASE-CONTROL STUDY USING MEDICARE 5% SAMPLE DATASETS
Takeshima T1, Tang W2, Iwasaki K2
1Milliman Inc., Tokyo, Japan, 2Milliman, Inc., Tokyo, Japan

PHP119
C22
ECONOMIC EVALUATION OF ENTEREX® IMX, A SPECIALIZED NUTRITION SUPPLEMENT CONTAINING ARGININE, IN THE TREATMENT OF NEUROCRITICAL PATIENTS IN MÉXICO
Paladio-Hernandez JA1, Marin M2
1Independent Researcher, Estado de México, Mexico, 2Victus, Miami, FL, USA

PHP120
C23
CHARACTERISTICS AND RATE OF SUBSEQUENT LUMBAR SPINE FUSION SURGERY AMONG PATIENTS TREATED WITH ALLOGENIC CELLULAR BONE MATRIX FOR POSTERIOR LUMBAR SPINAL FUSION
Corso KA1, Etter K2, Menzie AM3, Bhattacharyya S3, Pracyk JB4
1Johnson & Johnson, New Brunswick, NJ, USA, 2Johnson & Johnson Medical Devices, Raynham, MA, USA, 3DePuy Synthes, Inc., Raynham, MA, USA, 4Johnson & Johnson, Raynham, MA, USA

PHP121
C24
WITHDRAWN

PHP122
C25
WITHDRAWN

PHP123
C26
WITHDRAWN

PHP124
C27
WITHDRAWN

PHP125
C28
WITHDRAWN

PHP126
C29
WITHDRAWN

PHP127
C30
WITHDRAWN

PHP128
C31
THE STUDY OF THE PRESENT SITUATION AND PROBLEMS RELATED TO THE DRUG SAFETY MONITORING ACTED BY PHARMACISTS OF HOSPITALS UNDER THE NEW MEDICAL REFORM IN CHINA—BASED ON THE RESULT OF IN-DEPTH INTERVIEW
Wu H1, Qing L2, Zhang T1, Liu T2, Ran X1, Cai Y1, Ye J1, Yang X1, Long X1, He X1
1GuiZhou Medical University, GuiYang, China, 2Centers for Drug Evaluation and Reaserch of GuiZhou, GuiYang, China

PHP129
C32
EXPLORING USE OF REAL WORLD EVIDENCE (RWE) IN US VALUE ASSESSMENT FRAMEWORKS (VAFS)
Garg M
Sciformix, Westborough, MA, USA

PHP130
C33
GROWTH OF HOSPITAL-OWNED SPECIALTY PHARMACIES: IMPORTANCE AND IMPLICATIONS FOR MANUFACTURER CHANNEL AND PATIENT ACCESS STRATEGIES
Capuano C1, Curran K1, Bower D1, Walsh K2, Reddan J3
1Navigant Life Sciences, Boston, MA, USA, 2Navigant Life Sciences, London, UK, 3Navigant Life Sciences, Chicago, IL, USA

PHP131
C34
A NATURALISTIC OBSERVATION STUDY OF CURRENT MEDICATION COUNSELING PRACTICES AT RETAIL CHAIN PHARMACIES IN THE HOUSTON AREA
Yande S, Masurkar P, Gopinathan S, Sansgiry SS
College of Pharmacy, University of Houston, Houston, TX, USA

PHP132
C35
POTENTIAL IMPACT OF CHANGES TO BASKET OF COMPARATOR COUNTRIES FROM PMPRB7 TO PMPRB12 HAS ON CANADIAN PRODUCT LIST PRICES
McCormick J, Van Doorn-Drennan J, Minhas J, Millson B
IQVIA, Kanata, ON, Canada

PHP133
C36
DESIGNING EVIDENCE GENERATION PLANS FOR DIGITAL HEALTH TECHNOLOGIES TO GAIN REIMBURSEMENT COVERAGE IN THE US
Su W1, Lockwood C2, Chen F1
1IHS Markit, Washington, DC, USA, 2IHS Markit, Fremont, CA, USA

PHP134
C37
REIMBURSEMENT DECISION-MAKING IN UKRAINE: CURRENT AND FUTURE DIRECTIONS
Piniazhko O, Zaliska O, Ilyk R
Danylo Halytsky Lviv National Medical University, Lviv, Ukraine

PHP135
C38
IS EUNETHTA ENOUGH? THE REMAINING CHALLENGES IN NAVIGATING THE EARLY EUROPEAN REGULATORY AND HTA ADVICE
Macaulay R, Barkauskaite E
PAREXEL International, London, UK

PHP136
C39
REIMBURSEMENT OF MEDICINES IN UKRAINE: ISSUES AND CHALLENGES
Vashchenko O, Zalis'ka O
Danylo Halytsky Lviv National Medical University, Lviv, Ukraine

PHP137
C40
A REVIEW OF THE INTERNATIONAL NEW DRUG LANDSCAPE
Landry K, Lungu E
Patented Medicine Prices Review Board, Ottawa, ON, Canada

PHP138
C41
COMPARING LITERATURE REVIEW REQUIREMENTS FOR REIMBURSEMENT SUBMISSIONS ACROSS THE GLOBE
Fernandez MM1, Khan S2, Mordin M3, Copley-Merriman C3, McBride D4
1RTI Health Solutions, Research Triangle Park, NC, USA, 2RTI Health Solutions, Durham, NC, USA, 3RTI Health Solutions, Ann Arbor, MI, USA, 4RTI Health Solutions, Manchester, UK

HEALTH CARE USE & POLICY STUDIES - Health Care Research & Education
PHP139
C42
BUDGET IMPACT ANALYSES: INCONSISTENCY AND BIAS IN CHOICE OF REPORTING MEASURES
Potluri R1, Ranjan S2, Raj M2, Kumar A2, Bhandari H2
1SmartAnalyst Inc., New York, NY, USA, 2SmartAnalyst India Pvt. Ltd., Gurgaon, India

PHP140
C43
IS SELF-RATED HEALTH OF AMERICANS DIFFERENT IN 2017 COMPARED TO 2002?
Law EH1, Cha AS1, Shaw JW2, Pickard AS1
1University of Illinois at Chicago, Chicago, IL, USA, 2Bristol-Myers Squibb, Lawrenceville, NJ, USA

PHP141
C44
WHAT DOES “REAL WORLD” EVIDENCE MEAN? A REVIEW OF 2017 LITERATURE
Mordin M1, Buck PM1, Castro C2, Fernandez MM2, Hollis KA2, Ritchey ME2
1RTI Health Solutions, Ann Arbor, MI, USA, 2RTI Health Solutions, Research Triangle Park, NC, USA

PHP142
C45
INCREASING TREND TOWARD REPORTING SIGNIFICANT DIGITS IN UTILITY WEIGHTS – BEHAVIOR IMPLICATIONS OF “FLAT-OF-THE-CURVE” MEDICINE?
Hendrix N1, Adamson BJ2, Basu A3, Devine B3
1Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, University of Washington, Seattle, WA, USA, 2The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute,University of Washington, Seattle, WA, USA, 3University of Washington, Seattle, WA, USA

PHP143
C46
DO WORDS MATTER? PATIENT PERSPETIVES ON CONCEPTUALLY SIMILAR SYMPTOMS AND IMPACTS FREQUENTLY UTILIZED IN PATIENT-REPORTED OUTCOME (PRO) MEASURES
Gauthier M1, Egan S1, Ryan A2, Khurana L3, Dallabrida SM3, Evans C2
1Endpoint Outcomes, Long Beach, CA, USA, 2Endpoint Outcomes, Boston, MA, USA, 3ERT, Boston, MA, USA

PHP144
D1
IMPACT OF DIGITAL REMOTE HEALTH COACHING FOR PATIENTS WITH CHRONIC CONDITIONS ON QUALITY-ADJUSTED LIFE-YEARS
Burton S, Srivastava U, Patel D, Rasulnia M
Pack Health, Birmingham, AL, USA

PHP145
D2
THE COMPARISON OF CHINA EQ-5D-3L AND EQ-5D-5L VALUE SETS APPLIED IN GENERAL POPULATION
Zhou T, Ma A
China Pharmaceutical University, Nanjing, China

PHP146
D3
THE FREQUENCY AND AVAILABILITY OF POPULATION-SPECIFIC PATIENT REPORTED OUTCOME MEASURES AND MINIMAL CLINICALLY IMPORTANT DIFFERENCES AMONG APPROVED DRUGS IN CANADA
Soprovich AL, Ingstrup M, Eurich DT
University of Alberta, Edmonton, AB, Canada

PHP147
D4
RELATIONSHIP BETWEEN PATIENT CHARACTERISTICS AND LENGTH OF STAY FOR SEVERE BURN PATIENTS: ANALYSIS OF THE AMERICAN BURN ASSOCIATION NATIONAL BURN REPOSITORY
Kruger E1, Bilir SP1, Kowal S2, Han E2
1IQVIA, San Francisco, CA, USA, 2IQVIA, Fairfax, VA, USA

PHP148
D5
DEVELOPING CONTENT FOR A NEW GENERIC QALY MEASURE: RESULTS FROM A QUALITATIVE LITERATURE REVIEW (E-QALY PROJECT)
Mukuria C1, Connell J1, Carlton J1, Peasgood T1, Brazier J1, Scope A1, Clowes M1, Jones K2
1University of Sheffield, Sheffield, UK, 2University of Kent, Cantebury, UK

PHP149
WITHDRAWN

PHP150
D6
DOES EXPOSURE TO HEALTH VALUATION TASKS IMPACT ONE’S SELF RATED HEALTH?
Law EH, Hopkins T, Jiang R, Pickard AS
University of Illinois at Chicago, Chicago, IL, USA

PHP151
D7
THE ASSOCIATION BETWEEN MEDICATION SELF-MONITORING USING AN INCENTIVIZED DIGITAL HEALTH PROGRAM AND CLAIMS-BASED MEDICATION ADHERENCE
Jiang J1, Smith-Ray R1, Taitel MS1, Hou JG1, Singh T1, Orr G2
1Walgreen Co., Deerfield, IL, USA, 2Walgreens, Bellevue, WA, USA

PHP152
D8
PRESCRIPTION FILL RATES FOR ACUTE AND CHRONIC MEDICATIONS IN CLAIMS-EMR LINKED DATA
Park Y1, Yang H2, Das AK1, Yuen-Reed G3
1IBM Research, Cambridge, MA, USA, 2IBM Watson Health, Cambridge, MA, USA, 3IBM Watson Health, Tampa, FL, USA

PHP153
D9
WHAT US HEALTHCARE PROVIDERS VALUE IN GENOMIC PRECISION MEDICINE: A DISCRETE CHOICE EXPERIMENT
Dhanda DS1, Regier DA2, Veenstra DL1, Basu A3, Saha J1, Hendrix N1, Carlson JJ3
1Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, University of Washington, Seattle, WA, USA, 2Canadian Centre for Applied Research in Cancer Control (ARCC), British Columbia Cancer Agency, Vancouver, BC, Canada, 3University of Washington, Seattle, WA, USA

PHP154
D10
PATIENT-REPORTED OUTCOME MEASURES IN THE FDA PILOT COMPENDIUM: MEETING TODAY’S STANDARDS FOR PATIENT ENGAGEMENT IN DEVELOPMENT?
Oehrlein EM1, Perfetto EM2, Love TR2, Chung Y2, Ghafoori P2
1University of Maryland School of Pharmacy, Baltimore, IL, USA, 2University of Maryland School of Pharmacy, Baltimore, MD, USA

PHP155
D11
WITHDRAWN

PHP156
D12
WITHDRAWN

PHP157
D13
ONLINE METHODS FOR THE ELECTRONIC VALIDATION OF THE TREATMENT SATISFACTION FOR MEDICATION QUESTIONNAIRE
Rodriguez AM1, Williams P2, Palmer A3, Gemmen E3, Parmenter L4
1IQVIA, Madrid, Spain, 2IQVIA, Paris, France, 3IQVIA, Rockville, MD, USA, 4IQVIA, Reading, UK

PHP158
D14
WITHDRAWN

PHP159
D15
COMPARING RATES AND REASONS FOR MEDICATION NON-ADHERENCE ACROSS SEVENTEEN DISEASE CONDITIONS, THREE MODES OF ADMINISTRATION, AND TWO FREQUENCIES OF ADMINISTRATION, USING THE MEDICATION ADHERENCE REASONS SCALE (MAR-SCALE)
Unni E1, Goren A2
1Roseman University of Health Sciences, South Jordan, UT, USA, 2Kantar Health, New York, NY, USA

PHP160
WITHDRAWN

PHP161
D16
NEW ESTIMATES OF THE WILLINGNESS-TO-PAY FOR A STATISTICAL LIFE YEAR: A SYSTEMATIC REVIEW OF THE EMPIRICAL ECONOMIC LITERATURE
Schlander M1, Schwarz O2, Hernandez D1, Schaefer R1
1German Cancer Research Center (DKFZ), Heidelberg, Germany, 2Hochschule Heilbronn, Wiesbaden, Germany

PHP162
D17
SOCIODEMOGRAPHIC POPULATION AND HEALTH PROFILES OF SELF-IDENTIFIED MIDDLE EASTERN/NORTH AFRICAN MEDICAID BENEFICIARIES IN MANAGED CARE
Pradhan S1, Keleti D1, Kerrigan M1, Michael KE1, Chan H2, Gelzer AD1
1AmeriHealth Caritas, Philadelphia, PA, USA, 2Blue Cross Complete of Michigan, Southfield, MI, USA

PHP163
D18
A SYSTEMATIC REVIEW OF COST-EFFECTIVENESS ANALYSIS STUDIES IN NEWBORN SCREENING (NBS)
Algarni M1, Alolayan S2, Rittenhouse B3
1MCPHS university, Boston, MA, USA, 2Taibah University, MAdinah, Saudi Arabia, 3MCPHS University, Boston, MA, USA

PHP164
D19
WITHDRAWN

PHP165
D20
PATIENT DEFINITIONS OF IMPROVEMENT: MOST FREQUENT REASONS FOR DEFINING DISEASE IMPROVEMENT AS REPORTED BY PATIENTS WITH DIABETES, CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD), DEPRESSION OR OSTEOARTHRITIS (OA)
Egan S1, Gauthier M1, Cala ML2, Khurana L3, Dallabrida SM3, Evans C2
1Endpoint Outcomes, Long Beach, CA, USA, 2Endpoint Outcomes, Boston, MA, USA, 3ERT, Boston, MA, USA

PHP166
D21
EVALUATION OF ADHERENCE AND ITS PREDICTORS AMONG PERSONS OF ETHIOPIAN DESCENT IN WASHINGTON DC
AL-Matari RA, Maneno MK, Daftary M, Ettienne EB, Wingate LT, Hailemeskel B
Howard University, Washington, DC, USA

PHP167
D22
CLINICAL CORE OUTCOMES SETS IN REAL WORLD DATA
Ciani O1, Meregaglia M2, Jayawardana S3, Carney C3, Salcher M3, Williamson P4
1Centre for Research on Health and Social Care Management (CERGAS), Bocconi University, Milan, Italy, 2Bocconi University, Milan, Italy, 3London School of Economics and Political Science, London, UK, 4University of Liverpool, Liverpool, UK

PHP168
D23
WHY MOST BUDGET IMPACT ANALYSES OF MEDICINES ARE NOT ACCURATE? QUALITY OF BUDGET IMPACT ANALYSIS NEEDS TO BE IMPROVED
Hsu JC1, Ho M2, Tsai T2, Wu M3
1National Cheng Kung University, College of Medicine, Tainan, Taiwan, 2National Cheng Kung University, Tainan, Taiwan, 3National University of Tainan, Tainan, Taiwan

PHP169
D24
REPLICATING AND EXTENDING THE FOUR-FACTOR STRUCTURE OF THE MEDICATION ADHERENCE REASONS SCALE (MAR-SCALE) IN PAIN, MIGRAINE, AND SLEEP CONDITIONS AMONG PEOPLE USING DAILY AND WEEKLY ADMINISTERED ORAL MEDICATIONS
Goren A1, Unni E2
1Kantar Health, New York, NY, USA, 2Roseman University of Health Sciences, South Jordan, UT, USA

PHP170
E1
WITHDRAWN

PHP171
E2
DRIVERS OF GENOMIC PRECISION MEDICINE ADOPTION IN THE US: PAYER PREFERENCES
Dhanda DS1, Regier DA2, Veenstra DL1, Basu A3, Saha J1, Carlson JJ3
1Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute, University of Washington, Seattle, WA, USA, 2Canadian Centre for Applied Research in Cancer Control (ARCC), British Columbia Cancer Agency, Vancouver, BC, Canada, 3University of Washington, Seattle, WA, USA

PHP172
WITHDRAWN

PHP173
E3
HARNESSING BIG DATA: A METHODOLOGICAL APPROACH TO LINKING ELECTRONIC HEALTH RECORDS WITH PATIENT-REPORTED SURVEY DATA
Liebert R1, Lee LK2, Jaffe DH3, Doane MJ4, Haskell T4
1Kantar Health, New York, NY, USA, 2Kantar Health, San Mateo, CA, USA, 3Kantar Health, Tel Aviv, Israel, 4Kantar Health, Horsham, PA, USA

PHP174
E4
WITHDRAWN

PHP175
E5
QUANTIFYING THE ADDED SOCIETAL VALUE OF PUBLIC HEALTH INTERVENTIONS IN REDUCING HEALTH INEQUALITY
Griffin S1, Pennington R2, Owen L3, Love-Koh J1
1University of York, York, UK, 2University of Sheffield, Sheffield, UK, 3NICE, London, UK

PHP176
WITHDRAWN

PHP177
E6
CHARACTERIZATION OF OBSERVATIONAL PHASE IV STUDIES SUBMITTED TO CLINICALTRIALS.GOV BETWEEN 2007 AND 2017
Palacios L1, De Cock E2
1Syneos Health, Madrid, Spain, 2Syneos Health, Barcelona, Spain

PHP178
E7
AUTOMATION IN SYSTEMATIC LITERATURE REVIEW: CURRENTLY AVAILABLE TECHNOLOGIES AND DEPLOYMENT CHALLENGES
Mearns ES1, Sharma Y2, Gupta S2, Vedhera T2
1ZS Associates, New York, NY, USA, 2ZS Associates, Gurgaon, India

PHP179
E8
WITHDRAWN

PHP180
E9
THE IMPACT OF OPHTHALMOLOGY IN THE HUNGARIAN ONE-DAY SURGERY
Pónusz R1, Németh N1, Kovács D1, Varga V1, Gresz M2, Boncz I1, Endrei D1
1University of Pécs, Pécs, Hungary, 2National Healthcare Service Center, Budapest, Hungary

PHP181
E10
PATIENT PERFORMANCE INDICATORS: DECOMPOSITION OF PATIENT MEDICATION ADHERENCE
Yoder S, Wittenhagen L, Henderson S, Occhipinti M
Adheris Health, Newtown, PA, USA

PHP182
E11
WITHDRAWN

PHP183
E12
WITHDRAWN

PHP184
E13
HOW PATIENT ORGANIZATIONS ARE USING PATIENT-REPORTED OUTCOMES: SURVEY RESULTS FROM A NON-PROBABILITY SAMPLE OF PATIENTS COUNT NETWORK MEMBERS
Cusher T, McCleary KK, Grossman CI
FasterCures, Washington, DC, USA

PHP185
E14
PATTERNS OF NON-ADHERENCE TO ORAL ANTIVIRAL DRUGS
Morrison A, Kaufman AS
ScribCo, Effort, PA, USA

PHP186
E15
ANALYSIS THE NUMBER OF CASES OF ONE-DAY SURGICAL PATIENT CARE IN HUNGARIAN UNIVERSITY CLINICAL CENTRE’S BETWEEN 2010-2015
Pónusz R1, Németh N1, Kovács D1, Varga V1, Gresz M2, Boncz I1, Endrei D1
1University of Pécs, Pécs, Hungary, 2National Healthcare Service Center, Budapest, Hungary

PHP187
E16
SURVEY OF THE HUNGARIAN HEALTH CARE PRACTITIONERS’ ECONOMIC-MIGRATION AND CAREER CHANGING ATTITUDE
Kovács D, Pónusz R, Boncz I, Szabó Z, Endrei D
University of Pécs, Pécs, Hungary

PHP188
E17
AN ANALYSIS OF THE APPLICATIONS FOR CONFIRMATION ON WHETHER TO BELONG TO THE SUBJECTS OF THE NEW HEALTH TECHNOLOGIES ASSESSMENT IN KOREA
Hong MY, KIM SH, Lee SH, KIM AR, You MY
HIRA, wonju, Korea, Republic of (South)

PHP189
E18
BIOSIMILARS: THE CHALLENGE TO OVERCOME FINANCIAL INCENTIVES IN A US PAYER MARKET
Kuehn M, Densmore D
GfK Market Access, New York, NY, USA

PHP190
E19
SOCIAL MEDIA LISTENING FOR PATIENT RISK CHARACTERIZATION
Quartey G1, Ley-Acosta S1, Pierce C2, Nguyen A2, Ertle G1
1Genentech, South San Francisco, CA, USA, 2Booz Allen Epidemico, Boston, MA, USA

PHP191
WITHDRAWN

PHP192
E20
DRIVERS OF SOCIAL VALUE EXCEED LENGTH AND QUALITY OF LIFE: EVIDENCE FROM SWITZERLAND
Schlander M1, Telser H2, Fischer B2, Rechenberg Tv2, Schaefer R1, ESPM Project Group '3
1German Cancer Research Center (DKFZ), Heidelberg, Germany, 2Polynomics AG, Olten, Switzerland, 3Institute for Innovation & Valuation in Health Care, Wiesbaden, Germany

PHP193
E21
FINDINGS FROM THE 2018 INTERNATIONAL SOCIETY FOR PHARMACOECONOMICS AND OUTCOMES RESEARCH (ISPOR) STUDENT INTEREST SURVEY
Axon DR1, Bhattacharya K2, Adilgozhina G3, Milky G4, Jiang R5
1The University of Arizona, Tucson, AZ, USA, 2Center for Pharmaceutical Marketing and Management, University of Mississippi, University, MS, USA, 3Nazarbayev University, Astana, Kazakhstan, 4Purdue University, West Lafayette, IN, USA, 5University of Illinois at Chicago, Chicago, IL, USA

PHP194
E22
WHAT FACTORS MAY IMPACT THE LIKELIHOOD OF FIRST ABBREVIATED NEW DRUG APPLICATION (ANDA) SUBMISSION FOR A REFERENCE PRODUCT?
Wittayanukorn S1, Rosenberg M2, Schick A2, Hu M1, Wang Z1, Babiskin A1, Zhao L1
1Division of Quantitative Methods and Modeling, Office of Research Standards, Office of Generic Drugs, Center of Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA, 2Office of Program and Strategic Analysis, Center of Drug Evaluation and Research, U.S. Food and Drug Administration, Silver Spring, MD, USA

PHP195
E23
SALARY BENCHMARKS AND COMPENSATION DISPARITY AMONG GLOBAL HEALTH ECONOMICS AND MARKET ACCESS (HEORMA) PROFESSIONALS BASED ON A 2017 SELF-REPORT SURVEY
Shah A, Peeples P
HealthEconomics.Com, Ponte Vedra Beach, FL, USA

PHP196
E24
EXAMINING JOB SATISFACTION, STRESS, FLEXIBILITY, AND CAREER SUCCESS FACTORS IN THE HEALTH ECONOMICS, OUTCOMES RESEARCH, AND MARKET ACCESS (HEORMA) PROFESSION BASED ON A GLOBAL CROSS-SECTIONAL STUDY
Shah A, Peeples P
HealthEconomics.Com, Ponte Vedra Beach, FL, USA

PHP197
F1
SELF-REPORTED EXPERIENCES OF GENDER, RACE, AND IMMIGRATION RELATED DISCRIMINATION IN HEALTH ECONOMICS, OUTCOMES RESEARCH, AND MARKET ACCESS PROFESSIONS
Shah A, Peeples P
HealthEconomics.Com, Ponte Vedra Beach, FL, USA

PHP198
F2
A RASCH ANALYSIS OF STUDENT PHARMACISTS’ ATTITUDES TOWARDS HERBAL MEDICATIONS
Axon DR1, Augustine J2, Warholak T1, Lee JK1
1The University of Arizona, Tucson, AZ, USA, 2Mercer University College of Pharmacy, Atlanta, GA, USA

PHP199
F3
THE IMPACT OF NUTRITION-FOCUSED QUALITY IMPROVEMENT INTERVENTIONS ON LENGTH OF STAY AND READMISSION RATES AMONG HOSPITALIZED MALNOURISHED PATIENTS
Siegel S1, Fan L2, Goldman A1, Higgins J1, Goates S3, Partridge J3
1Sodexo, Maryland, USA; Catholic Heath Initiatives, Colorado, USA, Louisville, KY, USA, 2Abbott Nutrition, Abbott Park, IL, USA, 3Abbott Nutrition, Columbus, OH, USA

PHP200
F4
WITHDRAWN

PHP201
F5
EFFECT OF CASH PRESCRIPTIONS ON STATIN, ANTIHYPERTENSIVE, AND ANTIDIABETIC MEDICATION ADHERENCE ESTIMATES IN THE COMMERCIALLY-INSURED POPULATION
Thompson JA, Lin A, Heaton PC
University of Cincinnati, Cincinnati, OH, USA

HEALTH CARE USE & POLICY STUDIES - Health Technology Assessment Programs
PHP202
F6
IMPACT OF EUROPEAN MEDICINES AGENCY (EMA) CLINICAL TRIAL TRANSPARENCY POLICIES ON HEALTH TECHNOLOGY ASSESSMENT (HTA) DECISIONS IN THE UK
Cocklin S, Papanicolaou S, Jones C
PRMA Consulting, Fleet, UK

PHP203
F7
ANALYSIS OF SUCCESS RATES FOR THE CENTER FOR MEDICARE AND MEDICAID’S NEW TECHNOLOGY ADD-ON PAYMENT PROGRAM
Truglio A, Livoti C
Deerfield Management, New York, NY, USA

PHP204
F8
WITHDRAWN

PHP205
F9
REVEALED PREFERENCE FOR ADDITIONAL HEALTHCARE SPEND AND THE INSTITUTE FOR CLINICAL AND ECONOMIC REVIEW'S (ICER) BUDGET IMPACT THRESHOLD
Loftus BM, Campbell PR, Gaebler JA
Health Advances, Weston, MA, USA

PHP206
F10
HOW HEALTH TECHNOLOGY ASSESSMENT PROGRAMS TAKE INTO ACCOUNT THE PATIENT PERSPECTIVE IN HEALTHCARE DECISION MAKING: COMPARISON BETWEEN THE UNITED STATES AND SEVERAL EUROPEAN COUNTRIES
Sowell F1, Pantiri K2, Hensen M2, Walsh D3, Delbecque L2
1Pharmerit International, Bethesda, MD, USA, 2Pharmerit International, Rotterdam, The Netherlands, 3European Federation of Neurological Associations, Brussels, Belgium

PHP207
F11
WITHDRAWN

PHP208
WITHDRAWN

PHP209
F12
WITHDRAWN

HEALTH CARE USE & POLICY STUDIES - Patient Registries & Post-Marketing Studies
PHP210
F13
WITHDRAWN

PHP211
F14
WITHDRAWN

HEALTH CARE USE & POLICY STUDIES - Population Health
PHP212
F15
COMPARING COST-PER-QALYS GAINED AND COST-PER-DALYS AVERTED ANALYSES
Neumann PJ, Anderson JE, Panzer AD, Pope E, D'Cruz BN, Kim DD, Cohen JT
Tufts Medical Center, Boston, MA, USA

HEALTH CARE USE & POLICY STUDIES - Prescribing Behavior & Treatment Guidelines
PHP213
F16
TRENDS IN THE TEXAS PRESCRIPTION DRUG MONITORING PROGRAM: REGISTRATION AND UTILIZATION AMONG PHYSICIANS AND PHARMACISTS
Bapat S, Fleming ML, Thornton JD
College of Pharmacy, University of Houston, Houston, TX, USA

PHP214
F17
TRENDS IN BASELINE RETINAL EXAMINATIONS AND ASSOCIATED FACTORS AMONG NEW INITIATORS OF HYDROXYCHLOROQUINE IN MEDICARE: 2011-2015
Zhou L1, Kwoh CK1, Lo-Ciganic W2
1University of Arizona, Tucson, AZ, USA, 2The University of Arizona, Tucson, AZ, USA

PHP215
F18
CURRENT MANAGEMENT OF SPECIALTY DRUGS, SPECIALTY PHARMACIES AND BIOSIMILAR DRUGS
Brook RA1, Carlisle JA2, Smeeding JE3
1The JeSTARx Group & TPG-NPRT, Newfoundland, NJ, USA, 2The TPG-NPRT, Glastonbury, CT, USA, 3The TPG-NPRT & JeSTARx, Glastonbury, CT, USA

HEALTH CARE USE & POLICY STUDIES - Regulation of Health Care Sector
PHP216
F19
THE IMPACT OF LIFTING GOVERNMENT PRICE CONTROLS ON GLOBAL PHARMACEUTICAL INNOVATION AND POPULATION HEALTH
Schwartz TT1, Ward AS1, Xu X1, Sullivan J2
1Precision Health Economics, Oakland, CA, USA, 2Precision Health Economics, Boston, MA, USA

HEALTH CARE USE & POLICY STUDIES - Risk Sharing/Performance-Based Agreements
PHP217
F20
AGREEMENT BETWEEN FDA APPROVED DRUG LABEL AND PERFORMANCE-BASED RISK-SHARING ARRANGEMENT ENDPOINTS
Pham NN, Carlson JJ
University of Washington, Seattle, WA, USA

PHP218
F21
SURVEY RESULTS OF CONTEMPORARY US HEALTH PLAN POLICIES – AFFORDABLE CARE ACT (ACA), DIGITAL TECHNOLOGIES, VALUE BASED CONTRACTING (VBC) AND COMPARATIVE EFFECTIVENESS RESEARCH (CER)
Brook RA1, Carlisle JA2, Smeeding JE3
1The JeSTARx Group & TPG-NPRT, Newfoundland, NJ, USA, 2The TPG-NPRT, Glastonbury, CT, USA, 3The TPG-NPRT & JeSTARx, Glastonbury, CT, USA

PHP219
F22
COMMERCIALISING REGENERATIVE MEDICINES IN THE US – WHAT LESSONS CAN WE LEARN FROM EUROPE?
Macaulay R
PAREXEL International, London, UK

PHP220
F23
MISSION POSSIBLE? DEMONSTRATING ROBUST COST-EFFECTIVENESS WITHOUT ANY COMPARATIVE PHASE 3 DATA
Macaulay R1, Patel P2, Mcnaugton E1, Anell B3
1PAREXEL International, London, UK, 2PAREXEL International, Chandigarh, India, 3PAREXEL International, Stockholm, Sweden

PHP221
F24
THE OUT-OF-POCKET COST BURDEN OF PRESCRIPTION DRUGS: A PAN-CANADIAN COMPARISON
Kuo If1, Taylor K2, Bugden S1, Alessi-Severini S1
1University of Manitoba, Winnipeg, MB, Canada, 2Health Sciences Centre, Winnipeg, MB, Canada

Contact ISPOR @ info@ispor.org | View Legal Disclaimer
© 2018 International Society for Pharmacoeconomics and Outcomes Research.
All rights reserved under International and Pan-American Copyright Conventions.